BiotechTube

NNC9204-0530 + placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metabolism and Nutrition Disorder

Conditions

Metabolism and Nutrition Disorder, Obesity

Trial Timeline

Jul 26, 2016 → Jul 7, 2017

NCT ID
NCT02835235

About NNC9204-0530 + placebo

NNC9204-0530 + placebo is a phase 1 stage product being developed by Novo Nordisk for Metabolism and Nutrition Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02835235. Target conditions include Metabolism and Nutrition Disorder, Obesity.

What happened to similar drugs?

5 of 20 similar drugs in Metabolism and Nutrition Disorder were approved

Approved (5) Terminated (2) Active (15)
✅Xuezhikang Capsule + Atorvastatin Calcium TabletsAstraZenecaApproved
✅cyclosporine micro-emulsionNovartisApproved
✅Fluvastatin sodiumNovartisApproved
✅ezetimibeOrganonApproved
✅A single oral 5 mg of duterium labeled methamphetaminePacific BiosciencesApproved
🔄liraglutide + placebo + liraglutide + placeboNovo NordiskPhase 3
🔄liraglutide + placeboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02835235Phase 1Completed

Competing Products

20 competing products in Metabolism and Nutrition Disorder

See all competitors
ProductCompanyStageHype Score
mRNA-3704ModernaPhase 2
0
E2609EisaiPhase 1
29
E2006EisaiPhase 1
29
AZD3480 + Placebo + Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)AstraZenecaPhase 1
29
Xuezhikang Capsule + Atorvastatin Calcium TabletsAstraZenecaApproved
43
Rabeprazole or Esomeprazole or LanzoprazoleAstraZenecaPre-clinical
26
cyclosporine micro-emulsionNovartisApproved
35
Fluvastatin sodiumNovartisApproved
43
NNC0165-1562 + placeboNovo NordiskPhase 1
29
liraglutideNovo NordiskPhase 1
29
liraglutide + placeboNovo NordiskPhase 1
29
liraglutide + placebo + liraglutide + placeboNovo NordiskPhase 3
40
liraglutide + placeboNovo NordiskPhase 3
40
Liraglutide 3.0 mg + PlaceboNovo NordiskPhase 3
40
Semaglutide + Placebo (semaglutide)Novo NordiskPhase 3
40
liraglutide + orlistat + placeboNovo NordiskPhase 2
35
NNC 0070-0002-0453 + '2-0453 + placeboNovo NordiskPhase 1
21
NNC0194-0499 + PlaceboNovo NordiskPhase 1
29
Semaglutide + PlaceboNovo NordiskPhase 3
40
liraglutide + placeboNovo NordiskPhase 3
40